Japan· JP-4291466A1024
セミプリマブ（遺伝子組換え）
A medicinal product containing セミプリマブ（遺伝子組換え）, registered in Japan by リジェネロン・ジャパン, on the national reimbursement list.
Checked against MHLW / PMDA (Japan) on
Informational only — not a medical device.
The record
At a glance
MHLW / PMDA (Japan)- Active substance
- セミプリマブ（遺伝子組換え）
- Manufacturer
- リジェネロン・ジャパン
- Country
- Japan (JP)
- ATC code
- —
- Reimbursed
- Yes
- Source register
- MHLW / PMDA (Japan)
- Last checked
- October 2, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
セミプリマブ（遺伝子組換え） in 15 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- NorwayLibtayoAbacus Medicine A/S
- FinlandLIBTAYORegeneron Ireland Designated Activity Company (DAC)
- SpainLIBTAYO 350 MG CONCENTRADO PARA SOLUCION PARA PERFUSIONRegeneron Ireland Designated Activity Company
- United StatesLIBTAYORegeneron Pharmaceuticals, Inc.
- FranceLIBTAYO 350 mg, solution à diluer pour perfusionREGENERON IRELAND DESIGNATED ACTIVITY COMPANY (IRLANDE)
- BelgiumLibtayo 350 mgRegeneron Ireland Designated Activity Company (DAC)
- IrelandLIBTAYO 350 mg Concentrate for solution for infusionRegeneron Ireland U.C.
- IcelandLibtayoRegeneron Ireland Designated Activity Company
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Libtayo
- Liechtenstein · Libtayo
- Norway · Libtayo
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of MHLW / PMDA (Japan). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/2dffe2d7-39c8-4cd6-8f49-d8c96e9ac27c GET /v1/drugs/2dffe2d7-39c8-4cd6-8f49-d8c96e9ac27c?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"spec": "３５０ｍｇ７ｍＬ１瓶",
"marks": null,
"source": "mhlw",
"remarks": null,
"yj_code": "4291466A1024",
"category": "注射薬",
"price_yen": 450437,
"generic_name": "セミプリマブ（遺伝子組換え）",
"product_name_jp": null,
"therapeutic_class": "4291",
"transitional_expiry": null
}See everything about セミプリマブ（遺伝子組換え）.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.